IFFIm increases April 2026 vaccine bond by US$250 million to total US$1 billion

Responding to high interest from investors, the transaction on 18 November will provide an additional US$250 million for Gavi’s core immunisation programmes and the Gavi COVAX Advance Market Commitment (AMC). This is the first time IFFIm reached the $1 billion mark since its inaugural issuance in 2006 – a timely achievement for its 15th anniversary. “IFFIm’s tremendous success, particularly at this most pivotal moment in global health, has proven it was created for all the right reasons,” said Dr Seth Berkley, CEO of Gavi.

Read more:

IFFIm turns 15

15 years ago this month, IFFIm priced its very first “vaccination bond,” pioneering a bold new financial instrument with a clear humanitarian purpose: saving children’s lives. It raised $1 billion in immediately available funding for Gavi’s childhood vaccine programmes. Since then, our thriving partnership with donors, investors, the World Bank and Gavi has raised nearly $8 billion to help immunise more children sooner, to make vaccines more widely available, and, more recently, to support #COVAX to ensure all countries in the world have equitable access to COVID-19. Celebrate IFFIm’s history and share your memories with us on LinkedIn.

Read more.

Can dogs be trained to sniff out COVID-19?

The International Financing Facility for Immunisation Company
2 Lambs Passage, London EC1Y 8BB
United Kingdom

Forward to a friend
This email was sent by: Gavi, the Vaccine Alliance
Chemin du Pommier 40, Le Grand-Saconnex, Geneva, 1218 Switzerland
Privacy Policy
Update Profile
Manage Subscriptions
Unsubscribe